NEW YORK, NY / ACCESS Newswire / March 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

Merck (MRK) ended the recent trading session at $94.02, demonstrating a -0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.08%.

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Merck & Co. is making waves as an undervalued S&P 500 stock, boasting a forward P/E ratio of 10.52 and strong hedge fund ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

SeaStar Medical (Nasdaq: ICU) has been selected to receive the 2025 Corporate Innovator Award from the National Kidney ...

Drugmakers are urging the Trump administration and European Union officials to exempt medical goods from widening tariff wars, hoping to avert an ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

Merck & Co. Inc. closed 29.59% below its 52-week high of $134.63, which the company reached on June 25th.

Pharmaceutical giant Merck will close its plant in Northumberland County, Pennsylvania. According to a WARN Notice filed with ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...